Identification of new epitopes recognized by human monoclonal antibodies with neutralizing and antibody-dependent cellular cytotoxicity activities specific for human T cell leukemia virus type 1

M. Kuroki, M. Nakamura, Y. Itoyama, Y. Tanaka, H. Shiraki, Eishi Baba, T. Esaki, T. Tatsumoto, S. Nagafuchi, S. Nakano, Y. Niho

研究成果: ジャーナルへの寄稿記事

45 引用 (Scopus)

抄録

We have generated a number of EBV-transformed B cell lines producing human mAb against human T cell leukemia virus type 1 (HTLV-1) from the peripheral blood B lymphocytes obtained from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. Various synthetic peptides corresponding to antigenic regions of HTLV-1 gag and env proteins were used for the screening of antibodies in ELISA. In our study, four IgG mAb to the gag p19 amino acids 100 to 130, and 5 IgG mAb to the env p46 amino acids 175 to 199 were characterized. An immunofluorescence assay showed that all of these mAb specifically bound to the surface of HTLV-1-bearing cell lines. Among these mAb, one anti-gp46 mAb, designated KE36-11, neutralized the infectivity of HTLV-1 as determined by both the inhibition of HTLV-1-induced syncytium formation and transformation assays in vitro. An antibody-binding assay using overlapping oligopeptides revealed that KE36-11 recognized a new epitope locating between the gp46 amino acid sequence 187-193 (Ala-Pro-Pro- Leu-Leu-Pro-His). Another anti-gp46 mAb, designated KE36-7, showed antibody- dependent cellular cytotoxicity against HTLV-1-bearing cell line. KE36-7 bound strongly to the 10-mer peptide-gp46 187-196, and weakly to peptides containing the gp46 amino acid sequence 191-196 (Leu-Pro-His-Ser-Asn-Leu). These two epitopes, which are associated with HTLV-1 neutralization and antibody-dependent cellular cytotoxicity, are thus the first epitopes identified in human HTLV-1 infection. It is possible that passive immunization of humans with these two human mAb are effective on the protection of HTLV-1 infection in vivo.

元の言語英語
ページ(範囲)940-948
ページ数9
ジャーナルJournal of Immunology
149
発行部数3
出版物ステータス出版済み - 1 1 1992

Fingerprint

Deltaretrovirus
Neutralizing Antibodies
Epitopes
Monoclonal Antibodies
Antibodies
Virus Diseases
Peptides
Amino Acid Sequence
B-Lymphocytes
Immunoglobulin G
Tropical Spastic Paraparesis
env Gene Products
gag Gene Products
Amino Acids
Cell Line
Oligopeptides
Transformed Cell Line
Passive Immunization
Spinal Cord Diseases
Giant Cells

All Science Journal Classification (ASJC) codes

  • Immunology

これを引用

Identification of new epitopes recognized by human monoclonal antibodies with neutralizing and antibody-dependent cellular cytotoxicity activities specific for human T cell leukemia virus type 1. / Kuroki, M.; Nakamura, M.; Itoyama, Y.; Tanaka, Y.; Shiraki, H.; Baba, Eishi; Esaki, T.; Tatsumoto, T.; Nagafuchi, S.; Nakano, S.; Niho, Y.

:: Journal of Immunology, 巻 149, 番号 3, 01.01.1992, p. 940-948.

研究成果: ジャーナルへの寄稿記事

Kuroki, M, Nakamura, M, Itoyama, Y, Tanaka, Y, Shiraki, H, Baba, E, Esaki, T, Tatsumoto, T, Nagafuchi, S, Nakano, S & Niho, Y 1992, 'Identification of new epitopes recognized by human monoclonal antibodies with neutralizing and antibody-dependent cellular cytotoxicity activities specific for human T cell leukemia virus type 1', Journal of Immunology, 巻. 149, 番号 3, pp. 940-948.
Kuroki, M. ; Nakamura, M. ; Itoyama, Y. ; Tanaka, Y. ; Shiraki, H. ; Baba, Eishi ; Esaki, T. ; Tatsumoto, T. ; Nagafuchi, S. ; Nakano, S. ; Niho, Y. / Identification of new epitopes recognized by human monoclonal antibodies with neutralizing and antibody-dependent cellular cytotoxicity activities specific for human T cell leukemia virus type 1. :: Journal of Immunology. 1992 ; 巻 149, 番号 3. pp. 940-948.
@article{fe6638ae8b7c45249440456b0aac0cb3,
title = "Identification of new epitopes recognized by human monoclonal antibodies with neutralizing and antibody-dependent cellular cytotoxicity activities specific for human T cell leukemia virus type 1",
abstract = "We have generated a number of EBV-transformed B cell lines producing human mAb against human T cell leukemia virus type 1 (HTLV-1) from the peripheral blood B lymphocytes obtained from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. Various synthetic peptides corresponding to antigenic regions of HTLV-1 gag and env proteins were used for the screening of antibodies in ELISA. In our study, four IgG mAb to the gag p19 amino acids 100 to 130, and 5 IgG mAb to the env p46 amino acids 175 to 199 were characterized. An immunofluorescence assay showed that all of these mAb specifically bound to the surface of HTLV-1-bearing cell lines. Among these mAb, one anti-gp46 mAb, designated KE36-11, neutralized the infectivity of HTLV-1 as determined by both the inhibition of HTLV-1-induced syncytium formation and transformation assays in vitro. An antibody-binding assay using overlapping oligopeptides revealed that KE36-11 recognized a new epitope locating between the gp46 amino acid sequence 187-193 (Ala-Pro-Pro- Leu-Leu-Pro-His). Another anti-gp46 mAb, designated KE36-7, showed antibody- dependent cellular cytotoxicity against HTLV-1-bearing cell line. KE36-7 bound strongly to the 10-mer peptide-gp46 187-196, and weakly to peptides containing the gp46 amino acid sequence 191-196 (Leu-Pro-His-Ser-Asn-Leu). These two epitopes, which are associated with HTLV-1 neutralization and antibody-dependent cellular cytotoxicity, are thus the first epitopes identified in human HTLV-1 infection. It is possible that passive immunization of humans with these two human mAb are effective on the protection of HTLV-1 infection in vivo.",
author = "M. Kuroki and M. Nakamura and Y. Itoyama and Y. Tanaka and H. Shiraki and Eishi Baba and T. Esaki and T. Tatsumoto and S. Nagafuchi and S. Nakano and Y. Niho",
year = "1992",
month = "1",
day = "1",
language = "English",
volume = "149",
pages = "940--948",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "3",

}

TY - JOUR

T1 - Identification of new epitopes recognized by human monoclonal antibodies with neutralizing and antibody-dependent cellular cytotoxicity activities specific for human T cell leukemia virus type 1

AU - Kuroki, M.

AU - Nakamura, M.

AU - Itoyama, Y.

AU - Tanaka, Y.

AU - Shiraki, H.

AU - Baba, Eishi

AU - Esaki, T.

AU - Tatsumoto, T.

AU - Nagafuchi, S.

AU - Nakano, S.

AU - Niho, Y.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - We have generated a number of EBV-transformed B cell lines producing human mAb against human T cell leukemia virus type 1 (HTLV-1) from the peripheral blood B lymphocytes obtained from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. Various synthetic peptides corresponding to antigenic regions of HTLV-1 gag and env proteins were used for the screening of antibodies in ELISA. In our study, four IgG mAb to the gag p19 amino acids 100 to 130, and 5 IgG mAb to the env p46 amino acids 175 to 199 were characterized. An immunofluorescence assay showed that all of these mAb specifically bound to the surface of HTLV-1-bearing cell lines. Among these mAb, one anti-gp46 mAb, designated KE36-11, neutralized the infectivity of HTLV-1 as determined by both the inhibition of HTLV-1-induced syncytium formation and transformation assays in vitro. An antibody-binding assay using overlapping oligopeptides revealed that KE36-11 recognized a new epitope locating between the gp46 amino acid sequence 187-193 (Ala-Pro-Pro- Leu-Leu-Pro-His). Another anti-gp46 mAb, designated KE36-7, showed antibody- dependent cellular cytotoxicity against HTLV-1-bearing cell line. KE36-7 bound strongly to the 10-mer peptide-gp46 187-196, and weakly to peptides containing the gp46 amino acid sequence 191-196 (Leu-Pro-His-Ser-Asn-Leu). These two epitopes, which are associated with HTLV-1 neutralization and antibody-dependent cellular cytotoxicity, are thus the first epitopes identified in human HTLV-1 infection. It is possible that passive immunization of humans with these two human mAb are effective on the protection of HTLV-1 infection in vivo.

AB - We have generated a number of EBV-transformed B cell lines producing human mAb against human T cell leukemia virus type 1 (HTLV-1) from the peripheral blood B lymphocytes obtained from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. Various synthetic peptides corresponding to antigenic regions of HTLV-1 gag and env proteins were used for the screening of antibodies in ELISA. In our study, four IgG mAb to the gag p19 amino acids 100 to 130, and 5 IgG mAb to the env p46 amino acids 175 to 199 were characterized. An immunofluorescence assay showed that all of these mAb specifically bound to the surface of HTLV-1-bearing cell lines. Among these mAb, one anti-gp46 mAb, designated KE36-11, neutralized the infectivity of HTLV-1 as determined by both the inhibition of HTLV-1-induced syncytium formation and transformation assays in vitro. An antibody-binding assay using overlapping oligopeptides revealed that KE36-11 recognized a new epitope locating between the gp46 amino acid sequence 187-193 (Ala-Pro-Pro- Leu-Leu-Pro-His). Another anti-gp46 mAb, designated KE36-7, showed antibody- dependent cellular cytotoxicity against HTLV-1-bearing cell line. KE36-7 bound strongly to the 10-mer peptide-gp46 187-196, and weakly to peptides containing the gp46 amino acid sequence 191-196 (Leu-Pro-His-Ser-Asn-Leu). These two epitopes, which are associated with HTLV-1 neutralization and antibody-dependent cellular cytotoxicity, are thus the first epitopes identified in human HTLV-1 infection. It is possible that passive immunization of humans with these two human mAb are effective on the protection of HTLV-1 infection in vivo.

UR - http://www.scopus.com/inward/record.url?scp=0026693912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026693912&partnerID=8YFLogxK

M3 - Article

VL - 149

SP - 940

EP - 948

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 3

ER -